Overall, we found that the expressions of TPD52 and miR-223 were increased 23- and 2-fold in peripheral blood of cervical cancer patients, respectively, whereas expressions of KLF9 and PKCε were 0.14- and 0.05-fold reduced in cervical cancer patients relative to healthy individuals (Figure 6). This evidence concerns the gene TPD52 and cervical cancer.